GLC Medical (GLCM) Inc.
Health through Technology
GLC Medical (GLCM) Inc. is a Canadian biotechnology company focused to revolutionize diagnostic testing by leveraging new innovative technology with the aim to be a leader in the field, driving advancements in diagnostic accuracy, speed and accessibility.
Our expertise is in the early detection of a broad spectrum of pathogens and GLCM has developed a revolutionary breakthrough in biosensor technology.
GLCM's Approach: we utilize electrical impedance spectroscopy (EIS) in an encrypted cloud-based user app algorithm for secure data collection, analysis and result interpretation. We have developed and leveraged artificial intelligence (AI) software for diagnostics. This is a point-of-care platform that is accurate, reliable, and sensitive rapid testing (under 1-minute) for pathogens, without the need for expensive equipment and specialized human resources. EIS detects surface changes without labels like dyes, enzymes, or radioactive substances (nanoparticles).
Future Development: GLCM is focused to adapt the Platform for different pathogens, develop a multiplex testing platform, and create commercial value through real-world deployment into a global market. GLCM adheres to several of the UN Sustainable Development Goals, highlighting good health, partnerships, innovation and sustainable development goals. GLCM invites partnerships, projects, and stakeholders to contact us for more information.
Our Platform Product
First Vertical: SARS-CoV-2
The development of SARS-CoV-2 biosensors has been motivated by several factors. Firstly, the COVID-19 pandemic caused by SARS-CoV-2 has resulted in a global health crisis, with significant morbidity, mortality, and economic disruptions. The urgent need for rapid and accurate diagnostic tools to detect SARS-CoV-2 infections has driven the development of biosensors. Secondly, SARS-CoV-2 biosensors have the potential to provide immense economic value by enabling early detection, contact tracing, and targeted interventions. These biosensors can aid in curbing the spread of the virus, reducing healthcare costs associated with hospitalizations, and facilitating the safe reopening of economies. Lastly, the market potential for global care PoC diagnostics continues to be substantial with an anticipated growth to $49 billion by 2029, with a high demand for reliable and portable testing devices across various sectors, including healthcare, travel, and workplace safety. The development of cost-effective, sensitive, and user-friendly SARS-CoV-2 biosensors has the potential to have a transformative impact on public health and the global economy.
The key lesson that we have learned from the Covid-19 pandemic is that testing is essential.
Testing should generate fast and precise results - in under 1-minute;
Sample collection should be non-invasive to encourage more testing to better understand the virus to manage, treat and stop the spread;
Digital reading and reporting of data with the ability to read and report results digitally through cloud capabilities, enabling efficient data management and predictive software analysis;
The test should be portable and user-friendly with the capability to deploy into any community around the globe;
The capability to simultaneously test multiple samples and pathogens, to reduce the individual test time to results;
This test is our GLCM Biosensor Platform and is a tool for pandemic, epidemic and endemic preparedness.
Second Vertical: Respiratory Syncytial Virus (RSV) (proof-of-concept)
Respiratory syncytial virus (RSV) causes infections of the lungs and respiratory tract, and is a significant cause of respiratory infections, especially in infants, young children, and immunocompromised individuals, leading to substantial morbidity and mortality worldwide.
The need for rapid and accurate diagnostic tools to identify RSV infections is crucial for timely intervention and appropriate management. RSV biosensors have the potential to provide economic value by reducing healthcare costs associated with prolonged hospital stays, unnecessary treatments, and inappropriate antibiotic usage. Early and accurate detection can facilitate targeted antiviral therapies and help prevent the spread of RSV in healthcare settings. The market potential for RSV biosensors is substantial, given the high demand for point-of-care testing devices in clinics, hospitals, and resource-limited settings. The development of cost-effective, user-friendly, and sensitive RSV biosensors can address unmet diagnostic needs and have a positive impact on patient care and public health outcomes.
Third Vertical: E. coli (proof-of-concept)
Escherichia coli, also known as E. coli, is a member of a group of organisms which is common bacteria found in the digestive system of humans and animals. E.coli is a ubiquitous bacteria in our culture, and has caused countless problems in agricultural and food production settings through contamination of food products causing recalls and food poisoning. GLCM viewed this as an ideal target as E. coli testing should be used in conjunction with other indicators, as part of an approach to producing drinking water of an acceptable quality.
Drinking water sources are commonly impacted by fecal contamination from either human or animal sources and, as a result, may contain E. coli. Its presence in a water sample is considered a good indicator of recent fecal contamination. The ability to detect fecal contamination in drinking water is a necessity, as pathogenic microorganisms from human and animal feces in drinking water pose the greatest danger to public health. Rapid and reliable testing using GLCM’s Biosensor Test Platform, remains critical in mitigating the dangers of E. coli.
Future Vertical Development
Future developments on the platform include, but are not limited to,
RSV (Respiratory Syncytial Virus)
GLCM believes it can contribute greatly to the goal of reducing the impact of future pandemics and supports the mission of preventative pandemics in testing.
For Potential Users of the
GLCM Biosensor Platform
In The News
Looking for More?
We are expanding the global economy. The GLCM Biosensor Platform technology is available to license and will be a monumental product for future generations.
Modular integrations allow our technology to communicate with microelectronics. This can be utilized for real-time updates and relaying data to human resource managers and health associations.
GLC Medical is currently seeking strategic partners and welcomes all inquiries and discussions relating to the advancement of this breakthrough detection technology.
For more information, please email us at firstname.lastname@example.org